Numerion Labs vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Numerion Labs (fka Atomwise) deploys AtomNet deep learning for ultra-fast virtual drug screening; partnered with Sanofi for up to $1.2B in milestones; rebranded Oct 2025 with new APEX platform for hyper-scalable virtual library screening.
About
Numerion Labs, formerly known as Atomwise, is an AI-driven drug discovery company that uses deep learning to accelerate the identification of small molecule drug candidates. The company''s core technology, AtomNet, is a convolutional neural network trained on vast datasets of protein-ligand interactions to predict binding affinity and drug-likeness at scale. In October 2025, Atomwise rebranded as Numerion Labs, reflecting a sharpened strategic focus on ultra-fast virtual screening and the development of its APEX platform for hyper-scalable chemical library screening — a capability validated in partnership with NVIDIA.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.